We aspire to be the premier research-intensive biopharmaceutical company in the world and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals
Key findings from OASIS 4 Double-blind, placebo-controlled, 64-week, phase 3 trial (N=307) Mean weight loss: 13.6% (semaglutide) vs 2.2% (placebo) 5% weight loss in 79.2% (semaglutide) vs 31.1% (placebo) Improvements in physical functioning and cardiometabolic markers Serious adverse events were lower in the semaglutide group (3.9% vs 8.8%) This could be a key player particularly among patients who are needle-averse, travel often, or seek simpler dosing options
Thompson JP, Oegema TR Jr, Bradford DS
Het supplement is ontworpen als ondersteuning op de lange termijn, niet als een snelle oplossing
Dietary antioxidant vitamins, retinol, and breast cancer incidence in a cohort of Swedish women